Determining maximal tolerable dose of the monoclonal antibody BR96 labeled with90Y or177Lu in rats: Establishment of a syngeneic tumor model to evaluate means to improve radioimmunotherapy

Clinical Cancer Research

Volumn 11, Issue 19 II, 2005, Pages

  Mårtensson, Linda ^a,e   Wang, Zhongmin ^a,d   Nilsson, Rune ^b   Ohlsson, Tomas ^a   Senter, Peter ^c   Sjögren, Hans Olov ^a   Strand, Sven Erik ^a   Tennvall, Jan ^a  

^a LUND UNIVERSITY   (Sweden)

^b Mitra Medical AB   (Sweden)

^c Seattle Genetics   (United States)

^d SHANXI TUMOR HOSPITAL   (China)

^e LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; ANTIBODY CONJUGATE; AVIDIN; BIOTIN; CHELATING AGENT; CHIMERIC ANTIBODY; LUTETIUM; LUTETIUM 177; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY BR96; UNCLASSIFIED DRUG; YTTRIUM 90;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; BODY WEIGHT; BONE MARROW TOXICITY; CANCER IMMUNOTHERAPY; CHELATION; CONFERENCE PAPER; DISEASE SEVERITY; DOSE RESPONSE; HALF LIFE TIME; ISOTOPE LABELING; LEUKOCYTE COUNT; MALE; MAXIMUM TOLERATED DOSE; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; RAT; REPRODUCIBILITY; SKIN INFECTION; SOLID TUMOR; THROMBOCYTE COUNT; TREATMENT OUTCOME; TUMOR MODEL;

ANIMALS; ANTIBODIES, MONOCLONAL; BIOTIN; BODY WEIGHT; BRAIN; CHELATING AGENTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HETEROCYCLIC COMPOUNDS, 1-RING; LEUKOCYTES; LUTETIUM; MAXIMUM TOLERATED DOSE; PLATELET COUNT; RADIOIMMUNOTHERAPY; RADIOISOTOPES; RADIONUCLIDE IMAGING; RADIOPHARMACEUTICALS; RATS; TIME FACTORS; YTTRIUM RADIOISOTOPES;

EID: 26444618648     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-1004-0004     Document Type: Conference Paper

References (17)

1. Goldenberg DM. Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med 2002;43:693-713.
2. Paganelli G, Grana C, Chinol M, et al. Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin. Eur J Nucl Med 1999;26:348-57.
3. Garkavij M, Tennvall J, Strand SE, et al. Extracorporeal whole-blood immunoadsorption enhances radioimmunotargeting of iodine-125-labeled BR96-biotin monoclonal antibody. J Nucl Med 1997;38:895-901.
4. Hindorf C, Ljungberg M, Strand SE. Evaluation of parameters influencing s values in mouse dosimetry. J Nucl Med 2004;45:1960-5.
5. 131I. J Nucl Med 2001;42:967-74.
6. 186Re. J Nucl Med 2004;45:327-37.
7. Hellström I, Garrgigues HJ, Garrgigues U, Hellström K-E. Highly tumor-reactive, internalizing, mouse monoclonal antibodies to Le (y)-related cell surface antigens. Cancer Res 1990;50:2183-90.
8. Wilbur DS, Chyan MK, Hamlin DK, et al. Trifunctional conjugation reagents. Reagents that contain a biotin and a radiometal chelation moiety for application to extracorporeal affinity adsorption of radiolabeled antibodies. Bioconjug Chem 2002;13:1079-92.
9. Green NM. A Spectrophotometric assay for avidin and biotin based on binding of dyes by avidin. Biochem J 1965;94:23-4c.
10. 177Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin. J Nucl Med 2004;45:1224-32.
11. Stein R, Govindan SV, Griffiths GL, Hansen HJ, Goldenberg DM. Targeting and therapy of a human lung cancer xenograft using lutetium-177-labeled MAb RS7. Clin Cancer Res 1999;5(11 Suppl):3748s.
12. O'Donoghue JA, Bardiès M, Wheldon TE. Relationships between tumor size and curability for uniformly targeted therapy with β-emitting radionuclides. J Nucl Med 1995;36:1902-9.
13. Sjögren HO, Isaksson M, Willner D, Hellström I, Hellström KE, Trail PA. Antitumor activity of carcinoma-reactive BR96-doxorubicin conjugate against human carcinomas in athymic mice and rats and syngeneic rat carcinomas in immunocompetent rats. Cancer Res 1997;57:4530-6.
14. Chen JQ, Strand SE, Tennvall J, Lindgren L, Hindorf C, Sjogren HO. Extracorporeal immunoadsorption compared to avidin chase: enhancement of tumor-to-normal tissue ratio for biotinylated rhenium-188-chimeric BR96. J Nucl Med 1997;38:1934-9.
15. 125I- and (111)In-labeled monoclonal antibody BR96 for tumor targeting in combination with extracorporeal immunoadsorption. Clin Cancer Res 1999;5:3059-64s.
16. Tennvall J, Garkavij M, Chen J, Sjogren HO, Strand SE. Improving tumor-to-normal-tissue ratios of antibodies by extracorporeal immunoadsorption based on the avidin-biotin concept: development of a new treatment strategy applied to monoclonal antibodies murine L6 and chimeric BR96. Cancer 1997;15:2411-8.
17. Garkavij M, Tennvall J, Strand SE, et al. Extracorporeal immunoadsorption from whole blood based on the avidin-biotin concept. Evaluation of a new method. Acta Oncol 1996;35:309-12.